Solbinsiran

Solbinsiran, is a GalNAc conjugated small interfering RNA (siRNA) therapy, that targets angiopoietin-like 3. It is developed by Eli Lilly and Company to reduce the level of apolipoprotein B and reduce the risk of cardiovascular disease.

Mechanism of action
Solbinsiran is a GalNAc-conjugated Dicer-substrate siRNA (DsiRNA) that targets ANGPTL3 expression in the liver. ANGPTL3 plays a role in regulating lipid metabolism, and by inhibiting its expression, Solbinsiran aims to lower lipid levels, particularly triglycerides and low-density lipoprotein cholesterol (LDL-C) (Triglyceride Forum).

Preclinical and Clinical Research
In preclinical studies, Solbinsiran demonstrated significant reductions in human ANGPTL3 mRNA expression in hepatocytes and a substantial reduction in circulating ANGPTL3 protein levels in cynomolgus monkeys (Triglyceride Forum). In Phase 1 studies, it showed potential as a therapeutic option for reducing ANGPTL3 levels and triglycerides (TG) in patients with dyslipidemia (Triglyceride Forum).

Clinical applications
The therapy is currently investigational and has undergone testing in clinical settings for cardiovascular diseases.